A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Ganetespib (Primary) ; Sirolimus
- Indications Nerve sheath neoplasms
- Focus Adverse reactions
- 09 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 09 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.